C2/C3 alkynylation of <scp>l</scp>-ascorbic acid by Sonogashira coupling and efficient access to some potent and highly selective novel anticancer agents
作者:Santosh Rangnath Deshmukh、Shankar Ramchandra Thopate
DOI:10.1039/c8nj04477e
日期:——
exhibited superior potency against human MCF7, A549 and HT29 cancer cell lines. Compound 7k showed 2.7, 16.6 and 6.2 fold more potency against MCF7, A549 and HT29 cell lines, respectively, compared to doxorubicin and 643 fold more potency compared to AsA against the MCF7 cancer cell line. Notably, it showed 25 fold less cytotoxicity towards the normal human umbilical vein endothelial cell (HUVEC) line as
天然产物是开发新药的生物活性化合物的宝贵来源。本文中,我们报道了通过Sonogashira交叉偶联反应以中等至良好的产率合成L-抗坏血酸(AsA)的新型C2 / C3炔基衍生物的要求不高的合成方法。所有新的衍生物均显示出对人MCF7,A549和HT29癌细胞系的优越效力。复合7k分别显示出与阿霉素相比,对MCF7,A549和HT29细胞系的效力分别高出2.7、16.6和6.2倍,而与AsA相比,对MCF7癌细胞系的效力高出643倍。值得注意的是,与阿霉素抗癌药物相比,它对正常人脐静脉内皮细胞(HUVEC)的细胞毒性降低了25倍。令人愉快的是,与人正常细胞相比,它对人癌细胞的细胞毒性高333倍。流式细胞术研究表明,化合物4h和7k通过凋亡将A549细胞阻滞在G0 / G1期。此外,这些化合物具有很大的潜力被开发为有前途的抗癌药。